Revelation Biosciences Inc
REVB0.893USD
-0.008-0.87%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
3.20MMarket Cap
0.01P/E TTM
More Details of Revelation Biosciences Inc Company
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The Company's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The Company has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.
Revelation Biosciences Inc Info
Ticker SymbolREVB
Company nameRevelation Biosciences Inc
IPO dateOct 08, 2020
CEORolke (James M)
Number of employees8
Security typeOrdinary Share
Fiscal year-endOct 08
Address4660 Lajolla Village Drive
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92122
Phone16508003717
Websitehttps://www.revbiosciences.com/
Ticker SymbolREVB
IPO dateOct 08, 2020
CEORolke (James M)
Company Executives of Revelation Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. James M. Rolke
Mr. James M. Rolke
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
400.66K
+3888.25%
Ms. Jennifer A. Carver
Ms. Jennifer A. Carver
Independent Director
Independent Director
15.69K
+24801.59%
Dr. Lakhmir S. Chawla, M.D.
Dr. Lakhmir S. Chawla, M.D.
Independent Director
Independent Director
15.69K
+25614.75%
Mr. Jess Roper
Mr. Jess Roper
Independent Director
Independent Director
15.69K
+25614.75%
Mr. Chester S. Zygmont, III
Mr. Chester S. Zygmont, III
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. James M. Rolke
Mr. James M. Rolke
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
400.66K
+3888.25%
Ms. Jennifer A. Carver
Ms. Jennifer A. Carver
Independent Director
Independent Director
15.69K
+24801.59%
Dr. Lakhmir S. Chawla, M.D.
Dr. Lakhmir S. Chawla, M.D.
Independent Director
Independent Director
15.69K
+25614.75%
Mr. Jess Roper
Mr. Jess Roper
Independent Director
Independent Director
15.69K
+25614.75%
Mr. Chester S. Zygmont, III
Mr. Chester S. Zygmont, III
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 3
Updated: Wed, Dec 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armistice Capital LLC
6.83%
Rolke (James M)
6.76%
Zygmont (Chester Stanley III)
6.68%
Sabby Management, LLC
3.50%
DRW Securities, LLC
1.30%
Other
74.92%
Shareholders
Shareholders
Proportion
Armistice Capital LLC
6.83%
Rolke (James M)
6.76%
Zygmont (Chester Stanley III)
6.68%
Sabby Management, LLC
3.50%
DRW Securities, LLC
1.30%
Other
74.92%
Shareholder Types
Shareholders
Proportion
Individual Investor
14.24%
Hedge Fund
6.84%
Investment Advisor/Hedge Fund
3.51%
Investment Advisor
1.30%
Research Firm
0.26%
Other
73.84%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
22
75.14K
1.27%
+60.50K
2025Q2
27
26.98K
6.81%
+7.46K
2025Q1
31
80.08K
6.45%
+36.44K
2024Q4
34
35.76K
6.85%
+25.16K
2024Q3
35
6.58K
13.03%
+694.00
2024Q2
38
3.54K
13.80%
-587.00
2024Q1
39
864.00
11.20%
-2.83K
2023Q4
51
2.33K
90.40%
-1.57K
2023Q3
61
2.86K
55.32%
-403.00
2023Q2
67
2.58K
53.44%
+205.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
46.79K
2%
+36.88K
+371.84%
Sep 11, 2025
Rolke (James M)
10.05K
0.43%
--
--
Sep 11, 2025
Zygmont (Chester Stanley III)
5.03K
0.22%
+1.00
+0.02%
Sep 11, 2025
Sabby Management, LLC
21.93K
0.94%
+21.93K
--
Jun 30, 2025
Carver (Jennifer A)
63.00
0%
+1.00
+1.61%
Sep 11, 2025
Roper (Jess)
61.00
0%
--
--
Sep 11, 2025
Chawla (Lakhmir S)
61.00
0%
+1.00
+1.67%
Sep 11, 2025
Geode Capital Management, L.L.C.
--
0%
-228.00
-100.00%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 01, 2025
Merger
3→1
Jan 24, 2025
Merger
16→1
Jan 24, 2025
Merger
16→1
Jan 24, 2025
Merger
16→1
Jan 24, 2025
Merger
16→1
Jan 23, 2024
Merger
30→1
Date
Type
Ratio
Jul 01, 2025
Merger
3→1
Jan 24, 2025
Merger
16→1
Jan 24, 2025
Merger
16→1
Jan 24, 2025
Merger
16→1
Jan 24, 2025
Merger
16→1
Jan 23, 2024
Merger
30→1
Jan 23, 2024
Merger
30→1
Jan 23, 2024
Merger
30→1
Jan 23, 2024
Merger
30→1
Jan 31, 2023
Merger
35→1
View more
FAQs
Who are the top five shareholders of Revelation Biosciences Inc?
The top five shareholders of Revelation Biosciences Inc are:
Armistice Capital LLC holds 46.79K shares, accounting for 2.00% of the total shares.
Rolke (James M) holds 10.05K shares, accounting for 0.43% of the total shares.
Zygmont (Chester Stanley III) holds 5.03K shares, accounting for 0.22% of the total shares.
Sabby Management, LLC holds 21.93K shares, accounting for 0.94% of the total shares.
Carver (Jennifer A) holds 63.00 shares, accounting for 0.00% of the total shares.
Armistice Capital LLC holds 46.79K shares, accounting for 2.00% of the total shares.
Rolke (James M) holds 10.05K shares, accounting for 0.43% of the total shares.
Zygmont (Chester Stanley III) holds 5.03K shares, accounting for 0.22% of the total shares.
Sabby Management, LLC holds 21.93K shares, accounting for 0.94% of the total shares.
Carver (Jennifer A) holds 63.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Revelation Biosciences Inc?
The top three shareholder types of Revelation Biosciences Inc are:
Armistice Capital LLC
Rolke (James M)
Zygmont (Chester Stanley III)
Armistice Capital LLC
Rolke (James M)
Zygmont (Chester Stanley III)
How many institutions hold shares of Revelation Biosciences Inc (REVB)?
As of 2025Q3, 22 institutions hold shares of Revelation Biosciences Inc, with a combined market value of approximately 75.14K, accounting for 1.27% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -5.54%.
What is the biggest source of revenue for Revelation Biosciences Inc?
In --, the -- business generated the highest revenue for Revelation Biosciences Inc, amounting to -- and accounting for --% of total revenue.
